Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr

Pharmaceutical company Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr of 2011 compared to Rs 308 cr in a yr ago period.

Income are seen rising 8percent to Rs 2,091 cr compared to Rs 1,935 cr while the similar period.

EBITDA is likely to bounce 28percent to Rs 177 cr in July-September qtr of 2011 compared to Rs 139 cr in the similar qtr of last financial.

Operating_profit margin is anticipated to be at 8.5percent compared to 7percent yoy.

Be Sociable, Share!
Tags:

Stock Market Basics For Beginners

Advance Decline Index

Advance Decline Index A helpful instrument for discovering trend (bullish or bearish) in the share marketĀ  in which one divides the number of traded stocks that have increased ...…

Definition for Bond

Definition for Bond A bond is a debt security issued for a period of more than one year with the purpose of raising capital by borrowing. The bonds ...…

Definition for Share

Definition for Share The Certificates representing one unit of ownership in a mutual fund, corporation and limited partnership, the share has a certain declared face value, ...…

SEBI’s Role in an IPO Issue

SEBI’s Role in an IPO Issue Any firm doing a public issue or a listed firm building a rights issue of value of greater than Rs 50 lakh is needed to ...…

Meaning For Abridged Prospectus

Meaning For Abridged Prospectus 'Abridged Prospectus' is usually a shorter model of the-Prospectus and possesses all the significant features of a Prospectus. That accompanies the application-form of public issues - [ad ...…

Indian Share Tips

NSE Investment Site

Market Update

Share Guide

Designed by VMV
web
analytics